Fig. 5: Associations between SARS-CoV-2-specific T cells with patient or cancer-specific features. | Nature Cancer

Fig. 5: Associations between SARS-CoV-2-specific T cells with patient or cancer-specific features.

From: Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study

Fig. 5: Associations between SARS-CoV-2-specific T cells with patient or cancer-specific features.

a,b, Multivariate binary logistic regression analysis evaluating associations between SARS-CoV-2-specific CD4+ (a) and CD8+ (b) T cells with cancer diagnosis (solid versus hematological malignancies), comorbidities, age, sex and COVID-19 disease severity in 100 patients. Wald z-statistic was used to calculate two-sided P values. *P = 0.038. c,d, Multivariate binary logistic regression analysis evaluating associations between SARS-CoV-2-specific CD4+ (c) and CD8+ (d) T cells with anticancer intervention, age, sex and COVID-19 disease severity in patients with solid cancer (n = 81). Wald z-statistic was used to calculate two-sided P values. *P = 0.045. Dot denotes odds ratio (blue and red dots indicate positive or negative odds ratios, respectively); whiskers indicate 1.5 × IQR. e, Comparison of SARS-CoV-2-specific CD4+/CD8+ T cells between patients with solid malignancies taking CPIs (n = 13, administered within 3 months) and not on CPIs (n = 68). Boxes indicate the 25th and 75th percentiles, line indicates the median and whiskers indicate 1.5 × IQR. Dots represent individual samples. Significance was tested by two-sided Wilcoxon–Mann–Whitney U-test (P = 0.038 and P = 0.53).

Source data

Back to article page